[Prognostic factors of efficacy of eradication therapy in patients with duodenal ulcer].
The aim of the study was to determine microorganism-associated predictors of efficacy of eradication therapy in patients with Helicobacter pylori-associated duodenal ulcer. The subjects were 129 such patients. Clinical, endoscopic, microbiological, and immunological examination revealed differences in the initial immune status, the structure of gastroduodenal zone mucosa, and large bowel biocenosis, which predict efficacy of eradication therapy.
Kozlova
I V
IV
Eliseev
Iu Iu
IuIu
Pakhomova
A L
AL
Khan
Sadzhad Akhmad
SA
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000276:immunology; D001323:Autoantibodies / Q000097:blood; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D004384:Duodenoscopy; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007413:Intestinal Mucosa / Q000382:microbiology / Q000473:pathology; D012189:Retrospective Studies; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000907:Antibodies, Bacterial; D001323:Autoantibodies; D007136:Immunoglobulins